拉贝珠单抗

维基百科,自由的百科全书
拉贝珠单抗
单克隆抗体
种类完整抗体
目標癌胚抗原
臨床資料
ATC碼
  • 未分配
识别信息
CAS号219649-07-7  ☒N
ChemSpider
  • none
UNII
KEGG

拉贝珠单抗INN:labetuzumab;商品名CEA-CIDE)是一种人源化IgG1单克隆抗体,用于治疗结直肠癌[1]它选择性地结合CEACAM5英语CEACAM5[2]

该药物还被用在患有转移的甲状腺髓样癌患者中进行了测试。[3]

该药物由Immunomedics英语Immunomedics开发。

参考资料

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab (PDF). WHO Drug Information. 2002, 16 (1): 95. 
  2. ^ labetuzumab-SN-38 immunoconjugate IMMU-130. National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services. 
  3. ^ Stein, Rhona; Goldenberg, David M. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics. 2004-12, 3 (12). ISSN 1535-7163. PMID 15634649.